Dimension Therapeutics is a gene therapy company focused on developing novel therapies to treat rare diseases. Launched by Fidelity Biosciences in 2013, the Dimension team comprises biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. The company is focused on building its adeno-associated virus (AAV) therapeutic capabilities and advancing multiple gene therapy programs in rare diseases through partnerships with REGENX Biosciences and the University of Pennsylvania, which provide Dimension with exclusive gene therapy intellectual property and preferred access to multiple best-in-class AAV vectors based on REGENX's NAV technology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/23/14 | $30,000,000 |
OrbiMed Advisors | undisclosed | |
| 04/21/15 | $65,000,000 | Series B |
Jennison Associates New Leaf Venture Partners OrbiMed Advisors Partner Fund Management RA Capital Rock Springs Capital Tourbillon Global Ventures | undisclosed |
